RSVPreF3/AS01E RSV Vaccine

**Semantic type:** Immunologic Factor|Pharmacologic Substance

**Definition:** A respiratory syncytial virus (RSV) vaccine, that can potentially be used for the active immunization and prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 60 years of age and older. The RSVPreF3/AS01E RSV vaccine is composed of an antigen component, a recombinant RSV glycoprotein F stabilized in pre-fusion conformation (RSVPreF3), and an adjuvant component, AS01E, which is a liposomal formulation composed of 3-O-desacyl-4'-monophosphoryl lipid A (MPL) from Salmonella minnesota and QS-21, a saponin purified from plant extract Quillaja saponaria Molina. Upon reconstitution of the RSVPreF3 antigen component with the adjuvant AS01E and upon the intramuscular (IM) administration of the suspension, the RSVPreF3/AS01E RSV vaccine induces an active immune response against RSVpreF3 and induces neutralizing antibodies against RSV, thereby protecting against LRTD caused by RSV.

**Synonyms:** - Arexvy - RSV Vaccine RSVPreF3 Plus AS01E - RSVPreF3 Antigen Combined with AS01E - RSVPreF3 OA Vaccine - RSVPreF3 Older Adults Vaccine - Recombinant Subunit Pre-fusion RSV Glycoprotein Antigen Combined with AS01E - Respiratory Syncytial Virus Vaccine, Adjuvanted